ClinicalTrials.gg
RecruitingNCT05319158MIT-PBUpdated Dec 10, 2024

The Effect of the Movement Imitation Therapy in Preterm (MIT-PB) in Motor Behavior's Quality.

An interventional study of MIT-PB, movement imitation therapy for preterm. in Premature Birth, Risk and Early Intervention, sponsored by Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta. Recruiting at 3 sites in Spain. Open to participants aged 22 Weeks to 32 Weeks. Per ClinicalTrials.gov, last updated 2024-12-10.

Sponsored by Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
22 Weeks to 32 Weeks
Sex
All
01

Study summary

This study aims to assess the effect of a parent-administered intervention program based on MIT-PB in preterm with abnormal general movements during the preterm period. We will describe the short and long-term differences between infants exposed to MIT-PB and infants who follow current standard care.

Read the detailed description

The quasi-experimental design has been planned to assess the effect of a physiotherapy program carried out in neonatal intensive care and at home during the first months of life. Preterm babies born before 32 weeks gestational age (GA) and/or with less than 1500g showing an abnormal General Movement Assessment (GMA) at 34-36 weeks will be included.

Standardized tests will be performed at baseline, at term, 44 weeks post-menstrual age (PMA), 54 weeks PMA, 6 months, and 12 months.

A qualitative study has been designed to assess the physiotherapy performance and parents' experience.

Three different Hospitals with similar care protocols and sizes will recruit the sample (n=36). The Intervention groups (n=18) will be located at Hospital Josep Trueta of Girona and Hospital Sant Joan de Déu and the control group (n=18) will be located at Hospital Parc Taulí of Sabadell (Barcelona).

02

Conditions studied

  • Premature Birth
  • Risk
  • Early Intervention

Browse trials for

Keywords

  • neonatal therapy
  • general movements
  • high risk neurodevelopment
  • physiotherapy
03

In context

Premature Birth

2,550 studies on the registry are indexed under Premature Birth; 500 are open to participants now.

This study's planned enrollment of 36 is below the median of 84 across 1,666 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta is the lead sponsor of 31 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Weeks to 32 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm infants born before 32w GA and less than 1500g weight.
  • Infants who show Abnormal General Movements (CS-PR pattern) at 34-36w postmenstrual age (PMA).
  • Families able to understand/speak Catalan, Spanish or English.
  • Families willing to participate who have the

Exclusion criteria

Exclusion Criteria:

  • Infants with congenital abnormalities and/or genetic disorders
  • Infants with invasive ventilation or Continuous Positive Airway Pressure (CPAP) at 36 weeks PMA.
  • Infants with Normal General Movements at 34-36 w PMA.
  • Families not willing to participate.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Intervention group

    The group intervention will receive MIT-PB.

    Other: MIT-PB, movement imitation therapy for preterm.

  • No intervention
    control group

    The control group will receive standard care

Interventions

  • OtherMIT-PB, movement imitation therapy for preterm.

    The instant an infant showed CS or PR movements, the therapists (or a therapist and a parent) intervened by gently guiding the infants' limbs so as to maneuver and smoothen their movements, thereby imitating normal GM sequences as closely as possible, adding variability to the movement

06

What researchers measure

Primary outcomes

  1. The quality of General Movement by General Movements Optimality Score (GMOS-R) and Motor Optimality Score (MOS).

    We will videotape General Movements at 34, 38-40, 44 and 54 weeks PMA. The baseline measure( 34w) will be performed by the main researcher and an independent and experienced certified rater. This rater will be blind regarding infant group. The assessments at 38-40, 44 and 54 weeks will be performed by the independent, blind and certified rater in order to guarantee the study validity. The GMOS-R global assessment can be Normal (N), Poor Repertoire (PR), Cramped Syncronized (CS) or Chaotic (CH). On the detailed score ,the maximum value is 38. The MOS global assessment can be classified as Fidgety (F), Abnormal Fidgety (AF) or Absent Fidgety (F-). On the detailed score the maximum value is 28. Higher scores in both scales are correlated with better global outcome.

    Time frame: Each participant will be assessed from birth to the 54 weeks PMA.

Secondary outcomes

  1. Motor development by Hammersmith Infant Neurological Scale (HINE).

    Infants will assessed at 6 months CA by an independent neuro-pediatrician using the HINE. It is a standardized neurological exam for infants adjusted age 2 to 24 months. The HINE evaluates nerve function, movements, reflexes and reactions, posture, and tone and can help clinicians identify movement disorders including cerebral palsy (CP)The maximum global score is 78. Higher scores indicate better neurological performance.

    Time frame: 6 months CA

  2. Global development by Bayley III

    An independent neuropsychologists will assess Global Development by Bayley III at 12 months CA. Bayley-III provides information about whether a child's developmental trajectory in the cognitive domain is proceeding as expected, relative to same-age peers. It also includes a motor score, and fine and gross motor subtest scores. The assessment indicates mild, moderate or severe delay.

    Time frame: 12 months CA

Other outcomes

  1. Describe families experiences with the MIT-PB

    • Families will fill up a questionnaire at the end of the intervention to give their opinion about their experience with the therapy.

    Time frame: 6 months CA

  2. Study family's participation and treatment adherence

    Parents will get a software application in order to register the number of treatments achieved during the intervention period.

    Time frame: 6 months CA

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Mar 2026, 47 months after the start.

Of 741 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 47 months is above that.

Counting every sponsor, half of 759 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2022
First posted
Apr 8, 2022
StartActual
Apr 4, 2022
Primary completionEst.
Mar 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Dec 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05319158
Lead sponsor
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Collaborators
Hospital Sant Joan de Deu, Hospital Parc Taulí (Sabadell, Barcelona)
Responsible party
Susana Trallero Rodríguez (PhD candidate, MsC, Physiotherapist Susana Trallero Rodríguez, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta) — Principal investigator
First posted
Apr 8, 2022
Start date
Apr 4, 2022
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Dec 10, 2024

Study contacts

Susana Trallero, MsC
Contact
sue.trallero@gmail.com
34 + 675255810
Josep Perapoch, Dr
Contact
jperapoch.girona.ics@gencat.cat
620015414
Susana Trallero, MsC
principal investigator · International University of Catalonia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion